Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

1.

Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells.

Lum LG, Rathore R, Cummings F, Colvin GA, Radie-Keane K, Maizel A, Quesenberry PJ, Elfenbein GJ.

Clin Breast Cancer. 2003 Aug;4(3):212-7. No abstract available.

PMID:
14499016
[PubMed - indexed for MEDLINE]
2.

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura RY.

Breast Cancer. 2001;8(4):316-20. Review.

PMID:
11791124
[PubMed - indexed for MEDLINE]
3.

Trastuzumab (herceptin) for early-stage breast cancer.

Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M.

Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. Review.

PMID:
17512447
[PubMed - indexed for MEDLINE]
4.

Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer.

Wong WM.

Cancer Pract. 1999 Jan-Feb;7(1):48-50. Review. No abstract available.

PMID:
9893005
[PubMed - indexed for MEDLINE]
5.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Yaal-Hahoshen N, Safra T.

Isr Med Assoc J. 2006 Jun;8(6):416-21. Review. No abstract available.

PMID:
16833172
[PubMed - indexed for MEDLINE]
Free Article
6.

Trastuzumab : in HER2 and hormone receptor co-positive metastatic breast cancer.

Orman JS, Perry CM.

Drugs. 2007;67(18):2781-9. Review.

PMID:
18062723
[PubMed - indexed for MEDLINE]
8.

HER2-positive breast cancer: current treatment strategies.

Perez EA, Baweja M.

Cancer Invest. 2008 Jul;26(6):545-52. doi: 10.1080/07357900801971024. Review. No abstract available.

PMID:
18584344
[PubMed - indexed for MEDLINE]
9.

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.

Tokuda Y, Suzuki Y, Saito Y, Umemura S.

Breast Cancer. 2009;16(4):295-300. doi: 10.1007/s12282-009-0142-8. Epub 2009 Jul 17. Review.

PMID:
19609647
[PubMed - indexed for MEDLINE]
10.

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Goldenberg MM.

Clin Ther. 1999 Feb;21(2):309-18. Review.

PMID:
10211534
[PubMed - indexed for MEDLINE]
11.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

PMID:
16971734
[PubMed - indexed for MEDLINE]
Free Article
12.

Ongoing trials with trastuzumab in metastatic breast cancer.

Bell R.

Ann Oncol. 2001;12 Suppl 1:S69-73. Review.

PMID:
11521725
[PubMed - indexed for MEDLINE]
13.

Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.

Plosker GL, Keam SJ.

BioDrugs. 2006;20(4):259-62. Review.

PMID:
16831025
[PubMed - indexed for MEDLINE]
14.

Trastuzumab-based combination therapy for breast cancer.

Montemurro F, Valabrega G, Aglietta M.

Expert Opin Pharmacother. 2004 Jan;5(1):81-96. Review.

PMID:
14680438
[PubMed - indexed for MEDLINE]
15.

Current status of antibody therapy for breast cancer.

Toi M, Takada M, Bando H, Toyama K, Yamashiro H, Horiguchi S, Saji S.

Breast Cancer. 2004;11(1):10-4. Review.

PMID:
14718785
[PubMed - indexed for MEDLINE]
16.

Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.

Kabe KL, Kolesar JM.

Am J Health Syst Pharm. 2006 Mar 15;63(6):527-33. Review.

PMID:
16522889
[PubMed - indexed for MEDLINE]
17.

Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.

Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Mileshkin L, Snyder R, Michael M, Koczwara B.

Breast. 2011 Apr;20(2):101-10. doi: 10.1016/j.breast.2010.11.008. Epub 2010 Dec 22. Review.

PMID:
21183347
[PubMed - indexed for MEDLINE]
18.

Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.

Hortobagyi GN.

Semin Oncol. 2001 Dec;28(6 Suppl 18):43-7. Review.

PMID:
11774205
[PubMed - indexed for MEDLINE]
19.

Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.

Mehra R, Burtness B.

Expert Opin Biol Ther. 2006 Sep;6(9):951-62. Review.

PMID:
16918262
[PubMed - indexed for MEDLINE]
20.

Breast cancer. Clinical practice guidelines in oncology.

Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC; NCCN Breast Cancer Clinical Practice Guidelines Panel.

J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review. No abstract available.

PMID:
19200416
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk